0.80Open0.80Pre Close0 Volume1 Open Interest0.50Strike Price0.00Turnover0.00%IV13.04%PremiumSep 20, 2024Expiry Date0.65Intrinsic Value100Multiplier5DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.09Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Scilex Holding Stock Discussion
"As of June 30, 2024, the Company's negative working capital was $205.0million, including cash and cash equivalents of approximately$6.9million. During the six months ended June 30, 2024, the Company had operating losses of $35.1million and cash flows received from operations of $11.7million. The...
Benzinga· 2 mins ago
Scilex Expected to Be Majority Holder of Combined Co Following Completion of Deal
Denali Capital Acquisition: Combined Co to Be Renamed Semnur Pharmaceuticals, Inc., Common Stock to Be Listed on Nasdaq Under Ticker Symbols "Smnr"
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024
Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, will present research on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV, September 3-5, 2024. Key highlights include:
1. A non-CME presentation by Dr. Charles A...
1 min ago
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for Gloperba® Label
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label
Scilex Holding Company (Nasdaq: SCLX) announced FDA approval for label updates to GLOPERBA®, the first and only liquid oral version of colchicine for gout flare prophylaxis in adults. This approval allows for precision dosing, particularly beneficial for the 70% of gout patients with chronic kidney disease or gastrointestinal sensitivity who may require lower doses than the s...
No comment yet